Finasteride reduces the risk of incident clinical benign prostatic hyperplasia

J. Kellogg Parsons, Jeannette M. Schenk, Kathryn B. Arnold, Karen Messer, Cathee Till, Ian M. Thompson, Alan R. Kristal

Research output: Contribution to journalArticle

43 Scopus citations

Abstract

Background: Despite the high prevalence of clinical benign prostatic hyperplasia (BPH) among older men, there remains a notable absence of studies focused on BPH prevention. Objective: To determine if finasteride prevents incident clinical BPH in healthy older men. Design, setting, and participants: Data for this study are from the Prostate Cancer Prevention Trial. After excluding those with a history of BPH diagnosis or treatment, or an International Prostate Symptom Score (IPSS) ≥8 at study entry, 9253 men were available for analysis. Outcome measurements and statistical analysis: The primary outcome was incident clinical BPH, defined as the initiation of medical treatment, surgery, or sustained, clinically significant urinary symptoms (IPSS >14). Finasteride efficacy was estimated using Cox proportional regression models to generate hazards ratios (HRs). Results and limitations: Mean length of follow-up was 5.3 yr. The rate of clinical BPH was 19 per 1000 person-years in the placebo arm and 11 per 1000 person-years in the finasteride arm (p < 0.001). In a covariate-adjusted model, finasteride reduced the risk of incident clinical BPH by 40% (HR: 0.60; 95% confidence interval, 0.51-0.69; p < 0.001). The effect of finasteride on incident clinical BPH was attenuated in men with a body mass index ≥30 kg/m2 (pinteraction = 0.04) but otherwise did not differ significantly by physical activity, age, race, current diabetes, or current smoking. The post hoc nature of the analysis is a potential study limitation. Conclusions: Finasteride substantially reduces the risk of incident clinical BPH in healthy older men. These results should be considered in formulating recommendations for the use of finasteride to prevent prostate diseases in asymptomatic older men.

Original languageEnglish (US)
Pages (from-to)234-241
Number of pages8
JournalEuropean Urology
Volume62
Issue number2
DOIs
StatePublished - Aug 1 2012

Keywords

  • 5α-reductase inhibitor
  • Finasteride
  • Prevention and control
  • Prostatic hyperplasia
  • Prostatic neoplasm

ASJC Scopus subject areas

  • Urology

Fingerprint Dive into the research topics of 'Finasteride reduces the risk of incident clinical benign prostatic hyperplasia'. Together they form a unique fingerprint.

  • Cite this

    Parsons, J. K., Schenk, J. M., Arnold, K. B., Messer, K., Till, C., Thompson, I. M., & Kristal, A. R. (2012). Finasteride reduces the risk of incident clinical benign prostatic hyperplasia. European Urology, 62(2), 234-241. https://doi.org/10.1016/j.eururo.2012.03.007